EMA’s CHMP Is Set To Adopt Position On Another Avastin Biosimilar
Two EC Approvals, One Positive Opinion So Far
The market for biosimilar Avastin is set to form imminently, with two players holding final approvals from the European Commission waiting in the wings. In the coming days, the EMA’s Committee for Medicinal Products for Human Use is likely to issue an opinion on a further application.
